PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
22123108-4	2012	In addition, the nitecapone, another well-known COMT inhibitor, is also in preclinical development but for neuropathic pain.	nitecapone	17-27	catechol-O-methyltransferase	Homo sapiens	48-52
32397362-3	2020	In this study, protective effects of the ethyl acetate fraction of Acer okamotoanum (EAO) and isoquercitrin were evaluated on obesity and amyloidosis in the HFD- and Abeta-induced mouse model.	nitecapone	85-88	amyloid beta (A4) precursor protein	Mus musculus	166-171
32397362-6	2020	Administration of EAO and isoquercitrin significantly decreased body weight in HFD and Abeta-injected mice.	nitecapone	18-21	amyloid beta (A4) precursor protein	Mus musculus	87-92
32397362-9	2020	Moreover, administration of EAO and isoquercitrin groups down-regulated amyloidosis-related proteins in the brain such as beta-secretase, presenilin (PS)-1 and PS-2 compared with HFD and Abeta-injected mice.	nitecapone	28-31	amyloid beta (A4) precursor protein	Mus musculus	187-192
32397362-10	2020	This study indicated that EAO and isoquercitrin attenuated HFD and Abeta-induced obesity and amyloidosis, suggesting that they could be effective in preventing and treating both obesity and AD.	nitecapone	26-29	amyloid beta (A4) precursor protein	Mus musculus	67-72
33894646-3	2021	CD4 + T cells play a crucial role in EAO induction.	nitecapone	37-40	CD4 antigen	Mus musculus	0-3
32378542-0	2020	Crystal Structure of Catechol O-Methyltransferase Complexed with Nitecapone.	nitecapone	65-75	catechol-O-methyltransferase	Homo sapiens	21-49
32378542-4	2020	Here, a new crystal structure of COMT complexed with nitecapone (5), SAM and Mg2+ is revealed.	nitecapone	53-63	catechol-O-methyltransferase	Homo sapiens	33-37
21216640-3	2011	Since nitecapone, an inhibitor of catechol-O-methyl-transferase (COMT), has decreased neuropathic symptoms in diabetic rats, we studied its effects in another model of neuropathic pain, the spinal nerve ligation (SNL) model.	nitecapone	6-16	catechol-O-methyltransferase	Rattus norvegicus	34-63
20641250-15	2004	In clinical studies, AAAD is commonly inhibited with carbidopa, whereas COMT is blocked by entacapone and nitecapone.	nitecapone	106-116	catechol-O-methyltransferase	Homo sapiens	72-76
21216640-3	2011	Since nitecapone, an inhibitor of catechol-O-methyl-transferase (COMT), has decreased neuropathic symptoms in diabetic rats, we studied its effects in another model of neuropathic pain, the spinal nerve ligation (SNL) model.	nitecapone	6-16	catechol-O-methyltransferase	Rattus norvegicus	65-69
15864503-6	2005	Conversely, inhibition of COMT (nitecapone or Ro-41-0960, both 1 mM) slightly increased the basal levels of DA only in MTAL, whereas the percentage of added DA not metabolised rose to 97+/-10% in MTAL and to 91+/-15% in MCD.	nitecapone	32-42	catechol-O-methyltransferase	Rattus norvegicus	26-30
17705259-6	2007	Therefore, the capacity of three catechol-O-methyltransferase (COMT) inhibitors, entacapone, nitecapone, and tolcapone to protect ALP from oxidative damage was also investigated and found to be very similar to the most potent reference antioxidants.	nitecapone	93-103	alkaline phosphatase, placental	Homo sapiens	130-133
14654758-9	2003	In wild-type mice, the sodium-induced increase in blood pressure was completely normalized by treatment with the COMT inhibitor, nitecapone.	nitecapone	129-139	catechol-O-methyltransferase	Mus musculus	113-117
12028441-12	2002	Antioxidants, vitamin E and nitecapone, prevented AGE-dependent NF-kappaB activation and normalized PKC activity and associated TGF-beta1 transcription.	nitecapone	28-38	transforming growth factor, beta 1	Rattus norvegicus	128-137
9633684-4	1998	The new nitrocatechol-type COMT inhibitors entacapone, nitecapone, and tolcapone inhibit COMT in the periphery; tolcapone also inhibits COMT activity centrally.	nitecapone	55-65	catechol-O-methyltransferase	Homo sapiens	27-31
11318939-1	2001	BACKGROUND: In recent years, several nitrocatechol derivatives (tolcapone, entacapone, and nitecapone) have been developed and found to be highly selective and potent inhibitors of catechol-O-methyltransferase (COMT).	nitecapone	91-101	catechol-O-methyltransferase	Rattus norvegicus	181-209
11318939-1	2001	BACKGROUND: In recent years, several nitrocatechol derivatives (tolcapone, entacapone, and nitecapone) have been developed and found to be highly selective and potent inhibitors of catechol-O-methyltransferase (COMT).	nitecapone	91-101	catechol-O-methyltransferase	Rattus norvegicus	211-215
10923641-2	2000	In the present study, we examined the effect of nitecapone, an inhibitor of the dopamine-metabolizing enzyme catechol-O-methyl transferase (COMT) and a potent antioxidant, on functional and cellular determinants of renal function in rats with streptozotocin-induced diabetes.	nitecapone	48-58	catechol-O-methyltransferase	Rattus norvegicus	109-138
10923641-2	2000	In the present study, we examined the effect of nitecapone, an inhibitor of the dopamine-metabolizing enzyme catechol-O-methyl transferase (COMT) and a potent antioxidant, on functional and cellular determinants of renal function in rats with streptozotocin-induced diabetes.	nitecapone	48-58	catechol-O-methyltransferase	Rattus norvegicus	140-144
10923641-9	2000	The combined results suggest that the COMT-inhibitory and antioxidant properties of nitecapone provide a protective therapy against the development of diabetic nephropathy.	nitecapone	84-94	catechol-O-methyltransferase	Rattus norvegicus	38-42
10475405-11	1999	Myeloperoxidase activity in myocardial biopsies was higher in the control group (2.3 times higher at 5 minutes and 3.2 times higher at 10 minutes) than in the nitecapone group (p = 0.13).	nitecapone	159-169	myeloperoxidase	Homo sapiens	0-15
10369086-0	1999	Nitecapone inhibits myeloperoxidase in vitro and enhances functional performance after 8 h of ischemia in experimental heart transplantation.	nitecapone	0-10	myeloperoxidase	Homo sapiens	20-35
10369086-6	1999	In vitro studies were performed using sodium azide or nitecapone to inhibit myeloperoxidase (MPO) activity of isolated human leukocytes.	nitecapone	54-64	myeloperoxidase	Homo sapiens	76-91
10369086-6	1999	In vitro studies were performed using sodium azide or nitecapone to inhibit myeloperoxidase (MPO) activity of isolated human leukocytes.	nitecapone	54-64	myeloperoxidase	Homo sapiens	93-96
10369086-10	1999	In vitro studies demonstrated that NC inhibits 50% of purified MPO activity at a concentration of 10 microM.	nitecapone	35-37	myeloperoxidase	Homo sapiens	63-66
11161631-0	2001	Pain behavior and response properties of spinal dorsal horn neurons following experimental diabetic neuropathy in the rat: modulation by nitecapone, a COMT inhibitor with antioxidant properties.	nitecapone	137-147	catechol-O-methyltransferase	Rattus norvegicus	151-155
11161631-3	2001	A catechol-O-methyltransferase inhibitor with potent antioxidant properties, nitecapone, was used in an attempt to attenuate neuropathic symptoms.	nitecapone	77-87	catechol-O-methyltransferase	Rattus norvegicus	2-30
10644008-11	1999	A similar effect was seen when a catechol-O-methyltransferase (COMT) inhibitor (3-(3,4-dihydroxy-5-nitrobenzylidene)-2,4-pentanedione (OR-462) was utilised.	nitecapone	80-133	catechol-O-methyltransferase	Homo sapiens	33-61
10644008-11	1999	A similar effect was seen when a catechol-O-methyltransferase (COMT) inhibitor (3-(3,4-dihydroxy-5-nitrobenzylidene)-2,4-pentanedione (OR-462) was utilised.	nitecapone	80-133	catechol-O-methyltransferase	Homo sapiens	63-67
10644008-11	1999	A similar effect was seen when a catechol-O-methyltransferase (COMT) inhibitor (3-(3,4-dihydroxy-5-nitrobenzylidene)-2,4-pentanedione (OR-462) was utilised.	nitecapone	135-141	catechol-O-methyltransferase	Homo sapiens	33-61
10644008-11	1999	A similar effect was seen when a catechol-O-methyltransferase (COMT) inhibitor (3-(3,4-dihydroxy-5-nitrobenzylidene)-2,4-pentanedione (OR-462) was utilised.	nitecapone	135-141	catechol-O-methyltransferase	Homo sapiens	63-67
9826227-2	1998	Some COMT inhibitors may act entirely in the periphery (nitecapone, OR-462), while others may also have some activity in brain (entacapone, OR-611).	nitecapone	56-66	catechol O-methyltransferase	Macaca fascicularis	5-9
9633684-4	1998	The new nitrocatechol-type COMT inhibitors entacapone, nitecapone, and tolcapone inhibit COMT in the periphery; tolcapone also inhibits COMT activity centrally.	nitecapone	55-65	catechol-O-methyltransferase	Homo sapiens	89-93
9633684-4	1998	The new nitrocatechol-type COMT inhibitors entacapone, nitecapone, and tolcapone inhibit COMT in the periphery; tolcapone also inhibits COMT activity centrally.	nitecapone	55-65	catechol-O-methyltransferase	Homo sapiens	89-93
9358559-8	1997	The kinetic parameters for COMT inhibitors were in the following order: K(m) nitecapone > > entacapone > tolcapone; Vmax nitecapone > entacapone > tolcapone; Vmax/K(m) tolcapone > nitecapone > entacapone.	nitecapone	77-87	catechol-O-methyltransferase	Rattus norvegicus	27-31
9358559-8	1997	The kinetic parameters for COMT inhibitors were in the following order: K(m) nitecapone > > entacapone > tolcapone; Vmax nitecapone > entacapone > tolcapone; Vmax/K(m) tolcapone > nitecapone > entacapone.	nitecapone	130-140	catechol-O-methyltransferase	Rattus norvegicus	27-31
9358559-8	1997	The kinetic parameters for COMT inhibitors were in the following order: K(m) nitecapone > > entacapone > tolcapone; Vmax nitecapone > entacapone > tolcapone; Vmax/K(m) tolcapone > nitecapone > entacapone.	nitecapone	130-140	catechol-O-methyltransferase	Rattus norvegicus	27-31
9358559-11	1997	The different behaviour of nitecapone compared to the other COMT inhibitors may be due to its hydrophilic 5-substituent.	nitecapone	27-37	catechol-O-methyltransferase	Rattus norvegicus	60-64
8281420-9	1993	We conclude that nitecapone is an effective inhibitor of COMT in non-human primates.	nitecapone	17-27	catechol-O-methyltransferase	Homo sapiens	57-61
9291195-2	1997	To test whether the natriuretic effects of dopamine may be related to the rate of dopamine metabolism, rats were treated with nitecapone, a peripheral inhibitor of COMT.	nitecapone	126-136	catechol-O-methyltransferase	Rattus norvegicus	164-168
7575646-1	1995	The antioxidant properties of nitecapone, a catechol derivative and an inhibitor of catechol-O-methyltransferase, were reported recently.	nitecapone	30-40	catechol-O-methyltransferase	Rattus norvegicus	84-112
7835624-4	1994	Entacapone, nitecapone and tolcapone are nitrocatechol-type potent COMT inhibitors in vitro (Ki in nanomolar range).	nitecapone	12-22	catechol-O-methyltransferase	Homo sapiens	67-71
7835624-12	1994	In man, entacapone, nitecapone and tolcapone all inhibit dose dependently the COMT activity in erythrocytes.	nitecapone	20-30	catechol-O-methyltransferase	Homo sapiens	78-82
8001593-0	1994	Metabolite profiles of two [14C]-labelled catechol O-methyltransferase inhibitors, nitecapone and entacapone, in rat and mouse urine and rat bile.	nitecapone	83-93	catechol-O-methyltransferase	Rattus norvegicus	42-70
27520516-2	1994	Entacapone, nitecapone and to1capone are nitrocatechol- type agents that are potent COMT inhibitors in vitro and are active in vivo after oral administration.	nitecapone	12-22	catechol-O-methyltransferase	Homo sapiens	84-88
27520516-5	1994	In human volunteers, entacapone, nitecapone and tolcapone inhibit dose-dependently COMT activity of erythrocytes.	nitecapone	33-43	catechol-O-methyltransferase	Homo sapiens	83-87
8019435-3	1994	In the present study, we examined the effects of catechol derivatives, nitecapone and OR-1246, which have been identified to possess potent antioxidant properties, on NF-kappa B activation by monitoring its DNA binding activity.	nitecapone	71-81	nuclear factor kappa B subunit 1	Homo sapiens	167-177
8019435-4	1994	Both nitecapone and OR-1246 (10-300 microM) inhibited NF-kappa B activation induced by tumor necrosis factor-alpha in Jurkat T (acute human leukemia) cells.	nitecapone	5-15	nuclear factor kappa B subunit 1	Homo sapiens	54-64
8019435-4	1994	Both nitecapone and OR-1246 (10-300 microM) inhibited NF-kappa B activation induced by tumor necrosis factor-alpha in Jurkat T (acute human leukemia) cells.	nitecapone	5-15	tumor necrosis factor	Homo sapiens	87-114
8019435-8	1994	Hence, catechol derivatives inhibit NF-kappa B transcription factor through multiple mechanisms, and nitecapone and OR-1246 may be useful as therapeutic agents targeting NF-kappa B.	nitecapone	101-111	nuclear factor kappa B subunit 1	Homo sapiens	170-180
8482451-2	1993	This study was undertaken to investigate the effect of intraluminal nitecapone, a peripherally acting COMT inhibitor, on duodenal mucosal bicarbonate secretion in humans and to compare the effect with that of the prostaglandin E1 analogue misoprostol.	nitecapone	68-78	catechol-O-methyltransferase	Homo sapiens	102-106
8095035-1	1993	BACKGROUND: The catechol-O-methyl-transferase (COMT) inhibitor nitecapone, which prevents mucosal degradation of dopamine, and some dopamine receptor agonists ameliorate gastroduodenal mucosal damage.	nitecapone	63-73	catechol-O-methyltransferase	Rattus norvegicus	16-45
8097704-0	1993	Identification of major metabolites of the catechol-O-methyltransferase inhibitor nitecapone in the rat and dog.	nitecapone	82-92	catechol-O-methyltransferase	Rattus norvegicus	43-71
8097704-1	1993	Metabolites of nitecapone [3-(3,4-dihydroxy-5-nitrobenzylidene)-2,4-pentanedione], a potent catechol-O-methyltransferase inhibitor with gastroprotective and antiulcerogenic effects, were isolated by extraction and HPLC from dog and rat urine after enzymatic hydrolysis and as glucuronic acid and sulfate conjugates.	nitecapone	15-25	catechol-O-methyltransferase	Canis lupus familiaris	92-120
8095035-1	1993	BACKGROUND: The catechol-O-methyl-transferase (COMT) inhibitor nitecapone, which prevents mucosal degradation of dopamine, and some dopamine receptor agonists ameliorate gastroduodenal mucosal damage.	nitecapone	63-73	catechol-O-methyltransferase	Rattus norvegicus	47-51
8095035-7	1993	The dopamine D1 agonist SKF-38393 (10-50 micrograms/kg) and the COMT inhibitor nitecapone (50-500 micrograms/kg) caused dose-dependent increases in secretion, similar to that observed with dopamine.	nitecapone	79-89	catechol-O-methyltransferase	Rattus norvegicus	64-68
1884738-0	1991	Inhibition of human erythrocyte and gastroduodenal catechol-O-methyltransferase activity by nitecapone.	nitecapone	92-102	catechol-O-methyltransferase	Homo sapiens	51-79
8491246-1	1993	We have studied resting and exercise haemodynamics and catecholamine disposition after catechol-O-methyl-transferase (COMT) inhibition with nitecapone 100 mg t.d.s.	nitecapone	140-150	catechol-O-methyltransferase	Homo sapiens	118-122
1334029-1	1992	Nitecapone [3-(3,4-dihydroxy-5-nitrophenyl)methylene-2,4-pentanedione] [OR-462] is a catechol-O-methyltransferase inhibitor with gastroprotective properties.	nitecapone	0-10	catechol-O-methyltransferase	Homo sapiens	85-113
1334029-1	1992	Nitecapone [3-(3,4-dihydroxy-5-nitrophenyl)methylene-2,4-pentanedione] [OR-462] is a catechol-O-methyltransferase inhibitor with gastroprotective properties.	nitecapone	12-69	catechol-O-methyltransferase	Homo sapiens	85-113
1334029-1	1992	Nitecapone [3-(3,4-dihydroxy-5-nitrophenyl)methylene-2,4-pentanedione] [OR-462] is a catechol-O-methyltransferase inhibitor with gastroprotective properties.	nitecapone	72-78	catechol-O-methyltransferase	Homo sapiens	85-113
1421124-8	1992	Nitecapone and clorgyline decrease prolactin (PRL) levels below those reduced by LD/CD treatment.	nitecapone	0-10	prolactin	Rattus norvegicus	35-44
1734304-0	1992	[18F]-6-fluorodopa PET scanning in Parkinson"s disease after selective COMT inhibition with nitecapone (OR-462).	nitecapone	92-102	catechol-O-methyltransferase	Homo sapiens	71-75
1734304-1	1992	PET studies were performed to investigate the effects of a new cathechol-O-methyltransferase (COMT) inhibitor, nitecapone (OR-462 [3-(3,4-dihydroxy-5-nitrobenzylidene)- 2,4-pentadione]), on the accumulation of dopamine in the striatum and whether it is able to improve [18F]6-fluorodopa imaging of the brain.	nitecapone	111-121	catechol-O-methyltransferase	Homo sapiens	63-92
1734304-1	1992	PET studies were performed to investigate the effects of a new cathechol-O-methyltransferase (COMT) inhibitor, nitecapone (OR-462 [3-(3,4-dihydroxy-5-nitrobenzylidene)- 2,4-pentadione]), on the accumulation of dopamine in the striatum and whether it is able to improve [18F]6-fluorodopa imaging of the brain.	nitecapone	111-121	catechol-O-methyltransferase	Homo sapiens	94-98
1913700-1	1991	We studied the effectiveness of OR-611 and OR-462, two novel inhibitors of the enzyme catechol-O-methyltransferase (COMT), on 3-O-methyldopa (OMD) formation in cynomolgus monkeys following intravenous levodopa administration.	nitecapone	43-49	catechol O-methyltransferase	Macaca fascicularis	116-120
1888633-0	1991	COMT inhibition with nitecapone does not affect the tyramine pressor response.	nitecapone	21-31	catechol-O-methyltransferase	Homo sapiens	0-4
1888633-1	1991	Nitecapone (OR-462) is a new selective COMT inhibitor with gastroprotective properties.	nitecapone	0-10	catechol-O-methyltransferase	Homo sapiens	39-43
1888633-1	1991	Nitecapone (OR-462) is a new selective COMT inhibitor with gastroprotective properties.	nitecapone	12-18	catechol-O-methyltransferase	Homo sapiens	39-43
1888633-8	1991	COMT inhibition with nitecapone did not potentiate the haemodynamic responses to tyramine-induced catecholamine release.	nitecapone	21-31	catechol-O-methyltransferase	Homo sapiens	0-4
1884738-1	1991	The effect of increasing single oral doses of the novel catechol-O-methyltransferase (COMT) inhibitor, nitecapone, on enzyme activity in red cells (RBC) and gastroduodenal COMT activity has been studied in healthy male volunteers.	nitecapone	103-113	catechol-O-methyltransferase	Homo sapiens	56-84
1884738-1	1991	The effect of increasing single oral doses of the novel catechol-O-methyltransferase (COMT) inhibitor, nitecapone, on enzyme activity in red cells (RBC) and gastroduodenal COMT activity has been studied in healthy male volunteers.	nitecapone	103-113	catechol-O-methyltransferase	Homo sapiens	86-90
1884738-5	1991	The effect and the duration of the inhibition in RBC COMT was strongly correlated with plasma nitecapone concentrations in the dose range up to 150 mg. RBC COMT activity recovered fully in 4 h after medication.	nitecapone	94-104	catechol-O-methyltransferase	Homo sapiens	53-57
1884738-5	1991	The effect and the duration of the inhibition in RBC COMT was strongly correlated with plasma nitecapone concentrations in the dose range up to 150 mg. RBC COMT activity recovered fully in 4 h after medication.	nitecapone	94-104	catechol-O-methyltransferase	Homo sapiens	156-160
1884738-10	1991	The results confirm nitecapone as a potent COMT inhibitor in human tissues.	nitecapone	20-30	catechol-O-methyltransferase	Homo sapiens	43-47
2043724-0	1991	Determination of a catechol-O-methyltransferase inhibitor, nitecapone, in human plasma and urine by liquid chromatography.	nitecapone	59-69	catechol-O-methyltransferase	Homo sapiens	19-47
2043724-1	1991	Methods based on reversed-phase liquid chromatography with amperometric detection have been developed for determination of nitecapone, 3-(3,4-dihydroxy-5-nitrobenzylidene)-2,4-pentanedione, a COMT inhibitor, in human plasma and urine.	nitecapone	135-188	catechol-O-methyltransferase	Homo sapiens	192-196
2043724-4	1991	The methods are selective, sensitive and precise enough for determination of 4-5 ng ml-1 of nitecapone in plasma and urine and are thus suitable for the kind of pharmacokinetic studies exemplified in this paper.	nitecapone	92-102	interleukin 17F	Homo sapiens	84-88
1875781-7	1991	The specific COMT inhibitors, nitecapone and OR-611, effectively inhibited in vitro the human intestinal COMT activity.	nitecapone	30-40	catechol-O-methyltransferase	Homo sapiens	13-17
1875781-7	1991	The specific COMT inhibitors, nitecapone and OR-611, effectively inhibited in vitro the human intestinal COMT activity.	nitecapone	30-40	catechol-O-methyltransferase	Homo sapiens	105-109
2276119-2	1990	We studied the effect of nitecapone (OR-462), a novel inhibitor of catechol-O-methyltransferase (COMT), on OMD formation in cynomolgus monkeys following intravenous levodopa administration.	nitecapone	25-35	catechol O-methyltransferase	Macaca fascicularis	97-101
2276119-9	1990	In single-dose studies, OR-462 is an effective peripheral COMT inhibitor.	nitecapone	24-30	catechol O-methyltransferase	Macaca fascicularis	58-62
2289048-4	1990	COMT inhibitors nitecapone (OR-462) and OR-611 effectively inhibited human gastrointestinal COMT activity in vitro, the IC50 values ranging from 10-20 nM and 5-75 nM, respectively.	nitecapone	16-26	catechol-O-methyltransferase	Homo sapiens	0-4
2289048-4	1990	COMT inhibitors nitecapone (OR-462) and OR-611 effectively inhibited human gastrointestinal COMT activity in vitro, the IC50 values ranging from 10-20 nM and 5-75 nM, respectively.	nitecapone	16-26	catechol-O-methyltransferase	Homo sapiens	92-96
2289048-4	1990	COMT inhibitors nitecapone (OR-462) and OR-611 effectively inhibited human gastrointestinal COMT activity in vitro, the IC50 values ranging from 10-20 nM and 5-75 nM, respectively.	nitecapone	28-34	catechol-O-methyltransferase	Homo sapiens	0-4
2289048-4	1990	COMT inhibitors nitecapone (OR-462) and OR-611 effectively inhibited human gastrointestinal COMT activity in vitro, the IC50 values ranging from 10-20 nM and 5-75 nM, respectively.	nitecapone	28-34	catechol-O-methyltransferase	Homo sapiens	92-96
2113389-1	1990	Interactions between a selective catechol-O-methyltransferase (COMT) inhibitor OR-462 and a monoamine oxidase (MAO)-A inhibitor clorgyline were studied measuring concentrations of L-dopa, dopamine and their metabolites in the rat hypothalamus and striatum after administration of levodopa/carbidopa (15/30 mg/kg i.p.).	nitecapone	79-85	catechol-O-methyltransferase	Rattus norvegicus	63-67
2225697-0	1990	Exercise hemodynamics and catecholamine metabolism after catechol-O-methyltransferase inhibition with nitecapone.	nitecapone	102-112	catechol-O-methyltransferase	Homo sapiens	57-85
2272023-0	1990	Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers.	nitecapone	58-68	catechol-O-methyltransferase	Homo sapiens	18-46
2272023-1	1990	A new catechol-O-methyltransferase (COMT) inhibitor, nitecapone, was given in increasing doses of 0-100 mg concomitantly with L-Dopa/carbidopa (100/25 mg or 100/100 mg) to healthy male volunteers.	nitecapone	53-63	catechol-O-methyltransferase	Homo sapiens	6-34
2272023-1	1990	A new catechol-O-methyltransferase (COMT) inhibitor, nitecapone, was given in increasing doses of 0-100 mg concomitantly with L-Dopa/carbidopa (100/25 mg or 100/100 mg) to healthy male volunteers.	nitecapone	53-63	catechol-O-methyltransferase	Homo sapiens	36-40
2272023-5	1990	Nitecapone dose-dependently inhibited the soluble COMT activity in erythrocytes at 30 min after drug intake.	nitecapone	0-10	catechol-O-methyltransferase	Homo sapiens	50-54
2272023-10	1990	The biochemical changes in L-Dopa metabolism and erythrocyte COMT activity indicate that nitecapone is an active COMT inhibitor in humans, when given orally in single doses.	nitecapone	89-99	catechol-O-methyltransferase	Homo sapiens	61-65
2272023-10	1990	The biochemical changes in L-Dopa metabolism and erythrocyte COMT activity indicate that nitecapone is an active COMT inhibitor in humans, when given orally in single doses.	nitecapone	89-99	catechol-O-methyltransferase	Homo sapiens	113-117
2113389-4	1990	OR-462 was an effective COMT inhibitor at the doses 3 and 30 mg/kg i.p.	nitecapone	0-6	catechol-O-methyltransferase	Rattus norvegicus	24-28
2597177-0	1989	Inhibition of rat liver and duodenum soluble catechol-O-methyltransferase by a tight-binding inhibitor OR-462.	nitecapone	103-109	catechol-O-methyltransferase	Rattus norvegicus	45-73
8082488-4	1994	Dopamine D-1 receptor agonists and the peripherally acting catechol-O-methyl-transferase (COMT) inhibitor nitecapone stimulate the bicarbonate secretion in the rat and a similar increase in secretion has been observed in human volunteers.	nitecapone	106-116	catechol-O-methyltransferase	Rattus norvegicus	59-88
8082488-4	1994	Dopamine D-1 receptor agonists and the peripherally acting catechol-O-methyl-transferase (COMT) inhibitor nitecapone stimulate the bicarbonate secretion in the rat and a similar increase in secretion has been observed in human volunteers.	nitecapone	106-116	catechol-O-methyltransferase	Rattus norvegicus	90-94
34545698-0	2022	THE EQUINE METABOLISM OF THE CATECHOL-O-METHYLTRANSFERASE ENZYME INHIBITOR NITECAPONE.	nitecapone	75-85	catechol O-methyltransferase	Equus caballus	29-57
34545698-3	2022	A 200 mg dose of nitecapone, a COMT inhibitor, was administered to a thoroughbred horse and we have analysed the blood (<= 24 hours) and urine (<= 48 hours) samples that were collected.	nitecapone	17-27	catechol O-methyltransferase	Equus caballus	31-35
3171977-0	1988	Favorable effect of catechol-O-methyltransferase inhibition by OR-462 in experimental models of Parkinson"s disease.	nitecapone	63-69	catechol-O-methyltransferase	Rattus norvegicus	20-48
3171977-1	1988	A selective catechol-O-methyltransferase inhibitor, OR-462, was studied for its ability to affect pharmacokinetic properties of L-dopa after the p.o.	nitecapone	52-58	catechol-O-methyltransferase	Rattus norvegicus	12-40
3181288-2	1988	Two novel COMT inhibitors, OR-462 and OR-486, were highly effective (IC50 = 18 and 12 nM, respectively) and selective in inhibiting COMT activity in vitro.	nitecapone	27-33	catechol-O-methyltransferase	Rattus norvegicus	10-14
3181288-2	1988	Two novel COMT inhibitors, OR-462 and OR-486, were highly effective (IC50 = 18 and 12 nM, respectively) and selective in inhibiting COMT activity in vitro.	nitecapone	27-33	catechol-O-methyltransferase	Rattus norvegicus	132-136
3181288-8	1988	These results indicate that OR-462 and OR-486 are effective and long-lasting inhibitors of COMT activity.	nitecapone	28-34	catechol-O-methyltransferase	Rattus norvegicus	91-95